Genentech to restrict Avastin availability due to off-label use

10/11/2007 | Wall Street Journal, The · NYTimes.com

Genentech said it will halt the distribution of its cancer treatment Avastin to compounding pharmacies as more ophthalmologists recommend the drug's off-label use for wet age-related macular degeneration. The move is an attempt to promote Genentech's more-expensive eye drug Lucentis, which has lagged in sales, but Medicare says limiting distribution of the cancer drug could cost the system as much as $3 billion a year.

View Full Article in:

Wall Street Journal, The · NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ